If you have atrial fibrillation (AFib), your heart beats irregularly, raising the risk of stroke. For decades, warfarin was the go-to blood thinner to prevent clots. But a new analysis of multiple studies suggests that warfarin may actually be the least effective option for helping people live longer.
Researchers combined data from over 75,000 patients with non-valvular AFib (AFib not caused by a heart valve problem). They compared four treatments: warfarin, standard-dose NOACs (newer blood thinners like apixaban or rivaroxaban), low-dose NOACs, and a procedure called left atrial appendage occlusion (LAAO), which closes off a small pouch in the heart where clots often form.
The key finding: People taking warfarin had a higher risk of dying from any cause compared to those who got LAAO or either dose of NOACs. Specifically, the odds of death were 44% higher with warfarin versus LAAO, 13% higher versus low-dose NOACs, and 11% higher versus standard-dose NOACs. These differences were statistically significant, meaning they are unlikely to be due to chance.
When it came to preventing stroke or blood clots to the body, standard-dose NOACs ranked best. For major bleeding, low-dose NOACs came out on top. And for hemorrhagic stroke (bleeding in the brain), LAAO was the most effective. The study used a statistical method called SUCRA to rank treatments, but the exact numbers for these outcomes were not reported.
It is important to note that this is a network meta-analysis, which combines results from many studies. The quality of the original studies matters, and the analysis did not report on limitations or funding. Also, the study did not provide absolute numbers (like how many deaths per 100 people), so we cannot see the actual size of the benefit.
What does this mean for you? If you have AFib and are taking warfarin, do not stop. Talk to your doctor. This study adds to evidence that NOACs or LAAO may be better options, but treatment decisions are personal. Warfarin is still effective and may be right for some people. The takeaway is that newer options are worth discussing with your healthcare team.
